Mr. Tell has broad experience in finance, business development and strategy. He joins SyntheticMR from Siemens, where he most recently was of Head of Finance & Controlling for Siemens Real Estate, Sweden. Mr. Tell also has a background as an entrepreneur and holds an MBA from Henley Business School, University of Reading, London, U.K.
SyntheticMR's software for faster workflows and better decision support for MRI imaging, SyMRI® Diagnostics, was recently taken into clinical practice and the company is now entering the next phase, focusing global marketing and sales. "Mr. Tell's main task will be to establish SyMRI on an international market", says Andreas Bunge, Chairman of the Board in SyntheticMR and CEO of Accelerator Nordic AB.
For additional information please contact Andreas Bunge, CEO Accelerator Nordic AB,
+46 70 824 25 25.
Accelerator Nordic AB is a group of Life Science companies focused on pharmaceutical drug development and medical devices. Accelerator's subsidiaries have exposure towards large growth markets such as cancer therapy, medical imaging and orthopedics. The first medical device products are now on the market and a combination product is in clinical phase. The business model is centered on partnering or out-licensing. Accelerator Nordic is publicly traded on the Aktietorget exchange in Stockholm, Sweden. For more information please visit, www.acceleratorab.se
SyntheticMR AB, a subsidiary to Accelerator Nordic AB, has developed SyMRI Diagnostics, software for more effective Magnetic Resonance Imaging. SyMRI Diagnostics uses a rapid MRI scan that provides a measure for patient tissue properties. Using these properties conventional MRI images and tissue images can be generated. In this way examination time is reduced for the patient and the decision support is improved for the radiologist. For more information, please visit www.syntheticmr.se